Inclusion Criteria:  Patient with biochemical progression during ADT or combination therapies including ADT who are referred for imaging evaluation (prostate specific antigen [PSA] level >= 1 ng/ml that has increased on at least 2 successive occasions at least 1 weak apart)  Patients with bone scan scheduled or performed  Within 30 days of the PSMA PET, without any new prostate cancer (PCa) therapy in between Bone scans performed at University of California, Los Angeles (UCLA) and external institutions are eligible if Digital Imaging and Communications in Medicine (DICOM) images can be obtained, imported, and anonymized Patients enrolled in other clinical trials are eligible if they satisfy all other criteria of eligibility Patients or their legal representatives must have the ability to read, understand and provide written informed consent  Exclusion Criteria:  Initiation of a new therapy between the PSMA PET/CT and the bone scans Inability to provide written informed consent Known inability to remain still and lie flat for duration of each imaging procedure (about 30 minutes)